SCHEMBL29516148

SCHEMBL29516148

Cc1ccccc1Oc1nc(NS(=O)(=O)c2cnn(C)c2)nc2c1C(C)(C)CCC2

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 6/20 0.36
▸ HTR7 P34969 6/20 0.36
▸ DRD2 P14416 1/20 0.34
▸ HTR6 P50406 1/20 0.34
▸ THRB P10828 1/20 0.33
▸ SLC22A12 Q96S37 1/20 0.32
▸ NLRP3 Q96P20 1/20 0.32
▸ SLC6A2 P23975 1/20 0.31
▸ SLC6A4 P31645 1/20 0.31
▸ SLC6A3 Q01959 1/20 0.31
▸ PARG Q86W56 2/20 0.31
▸ EDNRA P25101 5/20 0.31
▸ EGFR P00533 1/20 0.31
▸ FGFR1 P11362 1/20 0.31
▸ KDR P35968 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24287494 1.00 HTR1A (0.36) HTR1AHTR7DRD2HTR6THRB
SCHEMBL26813358 0.87 HTR1A (0.36) HTR1AHTR7DRD2HTR6THRB
SCHEMBL29516117 0.87 HTR1A (0.36) HTR1AHTR7DRD2HTR6THRB
SCHEMBL26813338 0.82 HTR1A (0.36) HTR1AHTR7DRD2HTR6THRB
SCHEMBL24287273 0.82 HTR1A (0.36) HTR1AHTR7DRD2HTR6THRB
SCHEMBL29516324 0.82 HTR1A (0.36) HTR1AHTR7DRD2HTR6THRB
SCHEMBL29516391 0.82 HTR1A (0.36) HTR1AHTR7DRD2HTR6THRB
SCHEMBL24287499 0.80 — —
SCHEMBL26810510 0.76 HTR1A (0.36) HTR1AHTR7DRD2HTR6THRB
SCHEMBL24309827 0.76 HTR1A (0.43) HTR1AHTR7DRD2HTR6THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225750-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076629-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback